Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.

Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications

Chabbert-Buffet, Nathalie, Meduri, Geri, Bouchard, Philippe, Spitz, Irving M. · 2005 · Human Reproduction Update

Abstract

Since the discovery of the antiprogestin mifepristone, hundreds of similar compounds have been synthesized, which can be grouped in a large family of progesterone receptor ligands. This family includes pure agonists such as progesterone itself or progestins and, at the other end of the biological spectrum, pure progesterone receptor antagonists (PA). Selective progesterone receptor modulators (SPRM) have mixed agonist-antagonist properties, and occupy an intermediate position of the spectrum. These compounds have numerous applications in female health care. Mifepristone is used to terminate pregnancy, and as such is commercially available in many countries. The negative abortion-related image of mifepristone has clearly limited the involvement of the major pharmaceutical companies in the development of PA and SPRM. Many PA and SPRM display direct antiproliferative effects in the endometrium, although with variable actions which seem product- and dose-dependent. This property justifies their use in the treatment of myomas and endometriosis. PA also suppress late follicular development, block the LH surge and retard endometrial maturation, which renders them potential estrogen-free contraceptive drugs. SPRM such as asoprisnil are not as effective in blocking the LH surge and appear to target the endometrium directly and produce amenorrhoea. Interestingly, clinical data show that treatment with these compounds is not associated with hypo-estrogenism and bone loss. The potential clinical applications of these compounds cover a broad field and are very promising in major public health areas. These include emergency contraception, long-term estrogen-free contraception (administered alone, or in association with a progestin-only pill to improve bleeding patterns), myomas (where they induce a marked reduction in tumour volume and produce amenorrhoea) and endometriosis. Further developments might also include hormone replacement therapy in post-menopausal women, as well as the treatment of hormone-dependent tumours.

Overview

Integrity signals

Registry

Crossref · 10.1093/humupd/dmi002

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 156 references

Research works printed but not linked: 28

  1. 2001, Cancer Res, 61, 4576
  2. 2001, Hum Reprod, 16, 72
  3. 1997, Acta Obstet Gynecol Scand Suppl, 164, 75
  4. 2002, J Soc Gynecol Invest, 9
  5. 2003, J Soc Gynecol Invest, 10, 301A
  6. 1991, Obstet Gynecol, 77, 410
  7. 2003, Obstet Gynecol, 101, 243
  8. 1998, J Clin Endocrinol Metab, 83, 4092
  9. 1999, Recent Prog Horm Res, 291
  10. 2002, J Clin Endocrinol Metab, 87, 2960, 10.1210/jcem.87.6.8572 · doi:10.1210/jcem.87.6.8572 · Paper page
  11. 1996, J Clin Endocrinol Metab, 81, 1933
  12. 1994, Hum Reprod, 9, 202
  13. 1994, Hum Reprod, 9, 77
  14. 1998, Mol Endocrinol, 12, 278
  15. 1998, J Reprod Med, 43, 551
  16. 1998, Cancer Res, 58, 1860
  17. 2000, Anticancer Res, 20, 4889
  18. 1999, J Clin Endocrinol Metab, 84, 2963
  19. 1993, J Clin Endocrinol Metab, 76, 513
  20. 1994, Am J Obstet Gynecol, 170, 1623, 10.1016/S0002-9378(12)91826-8 · doi:10.1016/s0002-9378(12)91826-8
  21. 1987, Bull Cancer, 74, 455
  22. 1994, J Clin Endocrinol Metab, 78, 440
  23. 1993, Mol Endocrinol, 7, 1256
  24. 1993, Mol Endocrinol, 7, 1244
  25. 1996, Chin J Obstet Gynecol, 31, 624
  26. 1998, Hum Reprod, 13, 259
  27. 1998, Zhonghua Fu Chan Ke Za Zhi, 33, 490
  28. 1999, Mol Endocrinol, 13, 418

Cited by

See all 310

Metadata

Authors
Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M.
Venue
Human Reproduction Update
Published
2005-05-01
Volume
11
Issue
3
Pages
293-307
ISSN
  • 1355-4786 (ISSN-L)
  • 1460-2369
OpenAlex
W2147700987
Cited by
310
References
156
Citations by year
2026: 4 · 2025: 4 · 2024: 7 · 2023: 3 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 16 · 2018: 14 · 2017: 23 · 2016: 17 · 2015: 20 · 2014: 23 · 2013: 20 · 2012: 19
FWCI
2.86
Type
journal article
Language
en
Open access
closed
Locations
  • Human Reproduction Update (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
selective progesterone receptor modulators, antiprogestins, mifepristone, asoprisnil, uterine fibroids, endometriosis, emergency contraception, amenorrhea, bone loss, hormone replacement therapy, hormone-dependent tumors, abortion
MeSH terms
Endometriosis, Estrenes, Female, Gonanes, Humans, Leiomyoma, Norpregnadienes, Oximes, Oxytocics, Progesterone, Receptors, Progesterone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. https://app.cochat.ai/papers/10.1093/humupd/dmi002
The paper
Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005). Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reproduction Update. https://doi.org/10.1093/humupd/dmi002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.